BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX: RGN), announced today the results for its year ended December 31, 2006. The company reported a net loss of $8.3 million or $0.21 per share for the year ended December 31, 2006, compared with a net loss of $5.4 million or $0.15 per share for the year ended December 31, 2005. For the fourth quarter 2006 the company’s net loss was $1.6 million or $0.04 per share. The net loss resulted primarily from the continued research and development expenditures related to ongoing Phase II clinical trials to study the company’s product (Tß4) for the treatment of chronic dermal wounds, research and development efforts related to its technology platform, scale-up manufacturing and formulation efforts related to two anticipated clinical trials in the ophthalmic and cardiovascular fields, and administrative costs associated with managing the company’s projects. RegeneRx had approximately $17 million in cash and short-term investments at December 31, 2006.
